Abstract:
Summary
Selective α1-adrenoblokers are trought promising in curent conservative treatment of benign
prostatic hiperplasia (BPH). The trial of Alfuzosin (Dalfaz) included 26 BPH patients with iritative and
obstructive simptoms. The Dalfaz has a favorable effect on BPH: it improved quality of live, releived
obstructive symptoms, reduced amount of residual urine.
